title: Peritoneal mesothelioma: the site of origin matters.
abstract: The etiology, gender distribution, pathology, natural history, and treatment options for mesothelioma (MM) differ substantially depending on the site of origin. Peritoneal mesothelioma (MPeM) is a rare disease, comprising only approximately 10% to 15% of the 2,500 cases of MM diagnosed in the United States each year. Patients with MPeM are younger than patients with pleural MM, and a higher proportion, mostly women, are long-term survivors. Most MPeM is caused by asbestos exposure. Germ-line mutations of BAP1 (BRCA associated protein 1) can predispose to MM, uveal melanoma, and potentially other cancers. MPeM can be challenging to diagnose, and cytology is rarely helpful. Review by an experienced pathologist using a panel of at least two positive and two negative immunohistochemical stains is essential. The three major pathologic subtypes are epithelial, sarcomatoid, and biphasic. Most cases are epithelial; the others have a dismal prognosis. Two indolent subtypes of borderline malignant potential-well-differentiated papillary mesothelioma and benign multicystic mesothelioma-are more common in the peritoneum and are treated surgically. In highly selected patients receiving treatment at experienced referral centers, an aggressive locoregional strategy that combines cytoreductive surgery to remove all gross disease and hyperthermic intraperitoneal chemotherapy to treat residual microscopic tumors yields a 3-year survival of 60% and a median survival approaching 5 years, far better than expected from historic controls. This approach also provides durable palliation of malignant ascites in nearly all patients. Pemetrexed is the only U.S. Food and Drug Administration (FDA)-approved systemic chemotherapy for pleural MM. Largely on the basis of data from pharmaceutical registry studies, the activity of pemetrexed-based chemotherapy appears to be similar in pleural MM and MPeM.
authors.affiliation: From the Gastrointestinal Oncology and Mesothelioma Programs, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
authors.forename: Hedy Lee
authors.initials: HL
authors.lastname: Kindler
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001194:Asbestos / Q000633:toxicity; D065426:Cytoreduction Surgical Procedures; D005260:Female; D018095:Germ-Line Mutation; D006801:Humans; D006979:Hyperthermia, Induced; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008654:Mesothelioma / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D000086002:Mesothelioma, Malignant; D000068437:Pemetrexed / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D010997:Pleural Neoplasms / Q000209:etiology / Q000628:therapy; D017741:Survivors; D025521:Tumor Suppressor Proteins / Q000235:genetics; D043222:Ubiquitin Thiolesterase / Q000235:genetics; D014481:United States
chemical_list: C400134:BAP1 protein, human; D025521:Tumor Suppressor Proteins; D000068437:Pemetrexed; D001194:Asbestos; D043222:Ubiquitin Thiolesterase